文摘
肠易激综合征(IBS)患者直肠扩张表现出增强敏感性。直肠膨胀的生长激素抑制素模拟减少感知健康志愿者无需修改直肠阻力。我们评估octreotide是否也有类似的影响在diarrhea-prone IBS患者直肠感知和抵抗。南卡罗来纳州Octreotide(100毫克)。在双盲安慰剂注射8 IBS患者。直肠气球测量量,诱发增加水平的感知和intrarectal压力。安慰剂后,感知阈值、压力、紧迫性和最大耐受量被报道在18 + / - 5,46 + / - 8,72 + / - 7和102 + / - 10毫升的IBS患者,值小于我们观察到在健康的志愿者。随着octreotide,这些感觉被认为在高卷(40 + / - 10,89 + / - 16,167 + / - 20和202 + / - 25毫升,P < . 05),近似的反应在健康的志愿者。在每个体积和IBS患者表现出较高的直肠压力显示趋势直肠高电阻(0.13 + / - 0.02毫米汞柱/毫升)比我们观察到在健康的志愿者。这些异常被octreotide规范化。Octreotide没有阻止rectoanal抑制反射证实缺乏影响当地的直肠反射弧。 As with healthy volunteers, IBS patients with diarrhea experience reduced perception of rectal distention after octreotide. Octreotide also reduces elevated rectal pressures in IBS patients, in contrast to healthy volunteers. Thus, octreotide shows potential therapeutic benefit in IBS via dual effects on visceral afferent pathways and rectal wall stiffness.